ImmuCell Corporation
ICCC
NASDAQ·Healthcare·Biotechnology·Mkt cap $89.6M
$9.90
▼ -1.00%
P/E
117.02
Mkt Cap
$89.6M
52-Wk Range
$4.52–$12.10
52-Week Range
$4.52 - $12.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 50.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary passive immunotherapy technology for livestock disease prevention
- Established distribution network through animal health channels
- Specialized focus on high-value dairy and beef cattle markets
- FDA-recognized diagnostic and treatment products with regulatory approval
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Profitability at risk
Increasing demand for antibiotic-free livestock health solutions
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+2.1% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ICCC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of $0.20 vs $0.05 consensus (+300.0% surprise). Revenue of $7.2M vs $5.4M expected (+33.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+300.0%
Revenue trend · last 8Q
—
—
+11%
+18%
-8%
-2%
+28%
+12%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$6.0M
$7.8M
$8.1M
$6.4M
$5.5M
$7.6M
$10.4M
$7.2M
Margins · last 8Q
Gross
33.9%
Operating
-27.8%
Profit
25.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ICCC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related